Standout Papers

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma 2023 2026 2024108
  1. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (2023)
    Shukui Qin, Masatoshi Kudo et al. JAMA Oncology

Immediate Impact

23 standout
Sub-graph 1 of 9

Citing Papers

Noncoding RNAs in sepsis-associated acute liver injury: Roles, mechanisms, and therapeutic applications
2025 Standout
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2025 Standout
1 intermediate paper

Works of Yabing Guo being referenced

Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.
2024
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
2023 Standout

Author Peers

Author Last Decade Papers Cites
Yabing Guo 151 105 70 15 230
A. Forgione 105 54 50 15 267
Joanne O’Rourke 148 118 49 13 257
Cheng‐Qian Zhong 132 70 44 20 262
Wen‐Bin Ding 63 74 46 11 188
Manuel Delgado 112 135 39 19 265
M.L. González-Diéguez 133 126 25 17 199
Daniel Almquist 102 101 166 18 292
Sophie Dominguez 111 162 146 13 277
Jiali Chen 83 48 54 10 185
Yangqing Huang 87 121 109 21 273

All Works

Loading papers...

Rankless by CCL
2026